A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Kobayashi, Kazuma ^a,d   Tsuji, Akihito ^b   Morita, Sojiro ^a   Horimi, Tadashi ^a   Shirasaka, Tetsuhiko ^c   Kanematsu, Takashi ^d  

^a Kochi Municipal Central Hospital   (Japan)

^b Kochi Health Sciences Center   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MITOMYCIN C; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; FATIGUE; FEMALE; GALLBLADDER CARCINOMA; GASTROINTESTINAL HEMORRHAGE; HUMAN; JAUNDICE; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALE; MUCOSA INFLAMMATION; NAUSEA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING; BILE DUCT TUMOR; CARCINOMA; DOSE RESPONSE; GALLBLADDER TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; CARCINOMA; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745679599     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-121     Document Type: Article

References (30)

1. Bhargava R, Jani CR, Savarese DMF, O'donell JL, Stuart KE, Lim CMR: Gemcitabine and Irinotecan in Locally Advanced or Metasttic Biliary Cancer: Preliminary Report. Oncology 2003, 17:23-26.
2. Malik IA, Aziz Z, Zaidi SHM, Sethuraman G: Gemsitabine and Cisplatin Is a Highly Effective Combination Chemotherapy in Patients With Advanced Cancer of the Gallbladder. Am J Clin Oncol 2003, 26:174-177.
3. Lin MH, Chen JS, Chen HHW, Su WC: A Phase II Trial of Gemsitabine in the Treatment of Advanced Bile Duct and Periampullary Carcinomas. Chemotherapy 2003, 49:154-158.
4. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK: Phase II study of capesitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003, 14:1115-1120.
5. Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Tosiya Sato: Chemotherapy in the Treatment of Advanced Gallbladder Cancer. Oncology 2004, 66:138-142.
6. Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ: Gemsitabine concurrent with continuous infusiona15-fluorourasil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 2004, 15:770-774.
7. Ishikawa T, Horimi T, Shima Y, Okabayashi T, Nishioka Y, Hamada M, Ishikawa J, Tsuji A, Takamatsu M, Morita S: Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder. J Hepatobilliary Pancreat Surg 2003, 10:233-238.
8. Hejna M, Zielinski CC: Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy. Expert Rev Anticancer Ther 2001, 1:291-300.
9. Todoroki T: Chemotherapy for Gallbladder Carcinoma-A Surgeon's Perspective. Hepato-Gastroenterology 2000, 47:948-955.
10. Alberts SR, Fishkin PA, Burgart LJ, Cera PJ, Mahoney MR, Morton RF, Johnson PA, Nair S, Goldberg RM: CPT-11 for Bile-Duct and Gallbladder Carcinoma. A Phase II North Central Cancer Treatment Group (NCCTG) Study. Int J Gastrointestinal Cancer 2002, 32:107-11.
11. Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T: Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000, 18:315-329.
12. Hirata K, Mukaiya M, Yamamitsu S, Oikawa I, Takashima T, Katsuramaki T, Sasaki K, Denno R, Shirasaka T: Biochemical modulation therapy for pancreatic cancer. J Hepatobiliary Pancreat Sury 1998, 5:255-260.
13. Tanaka B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, Hirakawa K: Combination Phase I trial of a Novel Oral Fluorurasil Derivative S-1 with Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902). Clin Cancer Res 2004, 10:1664-1669.
14. Enjoji A, the Nagasaki Digestive Organ Cancer Chemotherapy Study-Group Japan: Combination chemotherapy of 5-fluorourasil and low-dose cisplatin in advanced and recurrent gastric cancer: a multicenter retrospective study in Nagasaki, Japan. Anticancer Res 2002, 22:1135-1139.
15. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K, Tanimoto M: Combination Chemotherapy with Continuous 5-Fluorourasil and Low-dose Cisplatin Infusion for Advanced Hepatocellular Carcinoma. Anticancer Res 2003, 23:1891-1898.
16. Mori S, Kunieda K, Sugiyama Y, Saji S: Prediction of 5-fluorourasil and cisplatin synergism for advanced gastrointestinal cancers using a collagen gel droplet embedded culture. Surg Today 2003, 33:577-583.
17. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S: Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Int J Oncol 2004, 24:807-813.
18. Nakata B, Chung KH-YS, Ogawa M, Ogawa Y, Yanagawa K, Muguruma K, Inoue T, Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa M: p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 1998, 28:595-598.
19. Hata Y, Morita S, Morita Y, Awatani T, Takasaki M, Horimi T, Zen Ozawa: Peripheral Insertion of a Central Venous Access Device Under Fluoroscopic Guidance Using a Peripherally Accessed System (PAS) Port in the Forearm. Cardiovasc Intervent Radiol 1998, 21:230-233.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweji J, Glabbeke MV, Oosterom ATV, Christian MC, Gwyther SG: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000, 92:205-216.
21. Lee MA, Woo IS, Kang JH, Hong YS, Lee KS: Gemsitabine and Cisplatin Combination Chemotherapy in Intrahepatic Cholangiocarcinoma as Second-line Treatment: Report of Four Cases. Jpn J Clin Oncol 2004, 34:547-550.
22. Malik IA, Aziz Z: Prospective Evaluation of Efficacy and Toxicity of 5-FU and Folinic Acid (Mayo Clinic Regimen) in Patients With Advanced Cancer of the Gallbladder. Am J Clin Oncol 2003, 26:124-126.
23. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, Awasthy BS: A Phase II study of gemsitabine and cisplatin in chemotherapy-naive, unresectable gallbladder cancer. Br J Cancer 2004, 90:1516-1520.
24. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T: Pharmakokinetic Study of S-1, a Novel Oral Fluorourasil Antitumor Drug. Clin Cancer Res 1999, 5:2000-2005.
25. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagasima F, Shirano K, Matsumura Y, Goto M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003, 89:2207-2212.
26. Maehara Y: S-1 in gastric cancer; a comprehensive review. Gastric Cancer 2003, 6:2-8.
27. Hyodo I, Nishina T, Moriwaki T, Endo S, Terao T, Hirao K, Nasu J, Hirasaki S, Endo H, Masumoto T, Tajiri H, Kurita A: A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer 2003, 39:2328-2333.
28. Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S: Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 2003, 6:45-49.
29. Tsujitani S, Fukuda K, Nobuyuki Kaibara N: Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer. Gastric Cancer 2003, 6:50-57.
30. Hayashi K, Imaizumi T, Kazumi Uchida, Kuramochi H, Takasaki K: High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1. Oncology Reports 2002, 9:1355-1361.